Eli Lilly (LLY)
The desk's stance
On our research list, not on the slate.
What the company does
The center of the map: Mounjaro and Zepbound made tirzepatide the best-selling drug franchise in pharma history, and Foundayo (orforglipron) — the once-daily oral GLP-1 pill approved in April 2026 — opened the floodgates to needle-averse patients without food/water restrictions.
Why it matters: Everyone else on this map is either chasing the obesity franchise, supplying it, deciding whether to pay for it, or watching their own patents expire while Lilly compounds.
Outlook: The small-molecule pill scales at traditional pharma margins rather than constrained biologics lines. With CVS Caremark restoring Zepbound to preferred formularies and unblocking Foundayo, the multi-blockbuster franchise is targeting $80B+ in 2026 revenue.
In short: Global pharmaceutical developer and manufacturer. Category: Mega-Cap Biopharma Growth Leader. Sector: Healthcare, Drug Manufacturers - General.
G-Street Value and Score
G-Street Value: $1,221.81, computed Oct 18, 2026 (confidence: high).
How we got there: 50% analyst leg $1221.81 (street consensus, after 8% optimism discount) + 50% GainStreet factor value $1349.65 (28.6× fwd EPS anchored to healthcare multiples) — capped at the analyst leg; factors never out-bull the street. 5 analyst targets have no linked source and are shown but not counted; this value will not open a position until they are sourced.
G-Street Score: 76 out of 100 (Strong).
- Top-line growth & guidance: 27 of 32
- Margin power: 15 of 15
- Revenue visibility & quality: 5 of 11
- Profitability & balance sheet: 16 of 24
- Capital allocation & governance: 5 of 6
- Valuation, sentiment & momentum: 8 of 12
Our current thesis
Updated Oct 17, 2026
The thesis
- Q2 revenue accelerated 47.7% YoY to $22.97B, vastly outperforming biopharma peers on volume.
- Dominant tirzepatide adoption across diabetes and obesity sustains elite 83.4% gross margins.
- Rich next-generation metabolic pipeline including retatrutide and oral incretins supports multi-year expansion.
Risks
- Forward P/E of 26.6x commands a steep valuation premium over peer averages near 18x.
- PBM rebate demands and potential net pricing pressure threaten long-term margin sustainability.
- Substantial $54.9B debt burden and heavy manufacturing capex restrict near-term free cash flow.
What we're watching
- Q3 2026 earnings release on October 29, 2026, evaluating consensus $22.50B revenue target.
- Commercial uptake and script trajectories for oral incretin therapy Foundayo.
- Retesting of 52-week high resistance at $1,292.65 heading into reporting.
Latest
Eli Lilly trades at $1,257.03 (~26.6x forward P/E) following Q2 2026 revenue accelerating 47.7% YoY to $22.97B and its fourth consecutive EPS beat ($8.38, +27.3% surprise). Shares have rallied 9.1% over the past month to approach 52-week highs of $1,292.65, driven by strong tirzepatide demand and elite 83.4% gross margins. With recent analyst revisions skewed downward (3 up vs 7 down), expectations are demanding heading into Q3 2026 earnings on October 29.
Key numbers
As of Oct 16, 2026: market cap $1.12T · revenue growth +47.7% year over year · gross margin 83.4% · net margin 33.5% · forward P/E 26.6 · next earnings Oct 29, 2026.
Decision history
- Aug 29, 2026 — Sold at $1,174.61: -0.1% since entry (Cut). The robot re-added Lilly on Tuesday with barely 2% left to its own value — the math said this trade was done before it started. We stamped take-profit the same day and today we clear the slot. Flat exit, nothing booked, and the bench spot goes to a real setup.
- Aug 27, 2026 — Buy Zone → Take Profit at $1,176.10. Overriding the robot again: it added Lilly 3% below our value and called it a buy — its own reason admits the upside is nearly gone. Quality name, finished trade. Flagged to book; GLP-1 can earn a re-entry at a real discount.
- Aug 27, 2026 — Moved to Buy Zone at $1,176.10. Added 25h ago on GLP-1 dominance; holding strong as upside approaches fair value.
On the Gainz Lab maps
Who it does business with
- Thermo Fisher Scientific supplies Eli Lilly — Bioprocessing & tools. The instruments, consumables, and bioprocessing capacity under every blockbuster pipeline on this map.
- Eli Lilly competes with Novo Nordisk — The obesity crown. Tirzepatide and the oral Foundayo launch opened a wide lead, while Novo defends with Wegovy, oral semaglutide, and CagriSema's pending FDA review.
- Viking Therapeutics competes with Eli Lilly — The next pill & shot. VK2735's subcutaneous Phase 3 (VANQUISH) and oral formulations challenge Zepbound and Foundayo on tolerability and weight loss.
- Amgen competes with Eli Lilly — MariTide vs Zepbound. A monthly shot against a weekly one: MariTide is Amgen’s high-stakes bid to make extended dosing intervals the competitive wedge.
- Pfizer competes with Eli Lilly — The $10B gatecrash. Pfizer is running 10 Phase 3 trials for Metsera's berobenatide (MET-097i), targeting a 2028 obesity launch to replace patent cliff revenues.
- Eli Lilly supplies CVS Health (Caremark) — Formulary restoration. CVS Caremark restored Zepbound to preferred status for October 2026 and removed the new-to-market block on Foundayo.
- Eli Lilly supplies The Patient — Zepbound & Foundayo (about $35.0B a year). The tirzepatide and orforglipron franchises represent the fastest-growing drug portfolio in pharmaceutical history.
In the Daily Brief
Named in 1 edition on 1 day.
- Jun 15, 2026: The Iran deal sank oil, the SpaceX IPO has tech buzzing, and we're eyeing small caps while Eli Lilly slips for the crime of inventing another miracle weight loss drug